Affymax Inc. (AFFY) Stock Quote

Detailed Quote for Affymax Inc. (AFFY)

close 52 Week Information

52 Week High

February 8, 2012

Close: 11.13

52 Week Low

August 11, 2011

Close: 3.93

Today

Last Price
10.52

Change $
0.01

Change %
0.09%

Tick

Bid
10.51

Bid Size
500

Ask
10.52

Ask Size
200

Open
10.82

High
10.83

Low
10.43

Prev Close
10.53

Last Trade
2:31

Volume
677.39 k

52 Wk Hi
11.13

52 Wk Low
3.93

Market Cap
375.88 m

Ex-Div Date
N/A

Div Rate
N/A

Yield
N/A

Shares
35,730,339

EPS (TTM)
-1.45

PE Ratio
N/A

close Exchange Information Listed On Nasdaq Global Select (NGS) Exchange
NGS

News and Media for Affymax Inc. (AFFY)

Sector News | Topic News

News for AFFY

Fri, Feb 10, 2012

9:00 AM

2012 Economic Outlook - Report Highlights Affymax, Inc. and Cavium Inc - Marketwire

Wed, Feb 08, 2012

4:00 PM

Affymax to Present at 14th Annual BIO CEO & Investor Conference - Business Wire

Thu, Feb 02, 2012

4:00 PM

Affymax Promotes Cynthia Smith to Vice President, Market Access and Commercial Development - Business Wire

Wed, Jan 04, 2012

5:15 PM

Affymax to Webcast Analyst Briefing Event - Business Wire

Thu, Dec 15, 2011

4:00 PM

Takeda and Affymax Provide Update on Peginesatide Commercialization Rights in Japan - Business Wire

Wed, Dec 07, 2011

7:57 PM

FDA Advisory Committee Voted in Favor of Benefit/Risk Profile for Peginesatide for Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis - Business Wire

More News for AFFY >>

Tags for Affymax Inc.

Research stocks or mutual funds related to Affymax Inc. by keywords or tags. Find companies that have a similar focus to AFFY. The keywords below have been associated to AFFY by either user submission or electronic means.

pharmaceutical sales data kidney disease causes biotechnology company biotech research pharmaceutical partnership what is kidney disease clinical trials liability clinical research trial diabetes kidney failure h1 receptor pharmaceutical market diet for kidney disease kidney pharmaceuticals companies pharmaceutical partners end stage renal failure kidney biopsy pharmaceutical investment niche pharmaceutical kidney dialysis kidney disease diet kidney cysts pharmaceutical training peptide transition partnership chronic kidney stage 4 kidney disease pharmaceutical research and development recombinant protein what is renal failure clinical research training kidney disease dogs the kidney scientific research dupont pharmaceuticals kidney failure causes kidney nutrition kidney disease stages kidney malfunction obesity research pharma industry research pharmaceutical software pharma manufacturing polycystic kidney protein research research consultants kidney location renal diets kv pharmaceutical company warrick pharmaceutical